Moximed

A rendering of the Misha device. [Image courtesy of Moximed]Moximed announced today that doctors completed the first commercial cases for its Misha knee system, an implantable shock absorber (ISA).

In April, the FDA granted Misha de novo clearance for the treatment of medial knee osteoarthritis (OA). Its indication covers people with medial knee OA who failed to find relief from non-surgical or surgical treatment. These patients continue to experience pain that interferes with daily activities. Patients eligible for Misha are ineligible for — or unwilling to undergo — joint replacement due to age or absence of advanced OA.

Fremont, California-based Moximed says Misha represents the world’s first implantable shock absorber (ISA) for the knee.

“We’ve had unsolicited online requests for access to the Misha knee system from over one hundred surgeons across the U.S., and we receive several online patient inquiries every day,” said Anton Clifford, founder and CEO…

[Image from MoximedKnee osteoarthritis (OA) treatment developer Moximed announced today that it raised $40 million in a Series C equity and debt financing.

Fremont, California-based Moximed will use the proceeds from the financing to pursue regulatory approvals and establish commercial infrastructure for its Misha knee system — the world’s first implantable shock absorber (ISA) for the knee.

According to a news release, Advent Life Sciences led the funding round, while it also included returning investors New Enterprise Associates (NEA), Future Fund, Vertex Healthcare, Gilde Healthcare, GBS Venture Partners and Morgenthaler Ventures. Runway Growth Capital provided debt financing.

Moximed designed its Misha system for implantation during an outpatient procedure to help people with mild to moderate osteoarthritis preserve their knee joints while living active lives.

The system has demonstrated the ability to alleviate pain, improve function and p…